Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06261125Phase 2Recruiting

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

Role: lead

NCT05557955Completed

Identification of Breath Biomarkers in Esophageal Cancer

Role: lead

NCT04005170Phase 2Completed

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Role: lead

NCT04167293Phase 2Unknown

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)

Role: lead

NCT03791905Phase 2Unknown

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Role: lead

NCT02403531Phase 2Completed

Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer

Role: lead

All 6 trials loaded